Track topics on Twitter Track topics that are important to you
BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - June 08, 2015) - Amarin Corporation plc (NASDAQ: AMRN) announced today the presentation of findings from a new in vitro
study at a peer-reviewed poster session at the American Diabetes Association Scientific Sessions in Boston, Massachusetts.
The poster, titled "Eicosapentaenoic Acid (EPA) Reduces Glucose-induced Small Dense Low-Density Lipoprotein Oxidation
In Vitro in a Manner Distinct from Other Triglyceride-Lowering Agents and Vitamin E,
" presents data that shows exposure to eicosapentaenoic acid (EPA), an omega-3 fatty acid, inhibited glucose-induced oxidation of small dense LDL. This study examined the effects of EPA and other triglyceride-lowering agents on human sdLDL oxidation following exposure in vitro
to hyperglycemic conditions. Exposure to hyperglycemic conditions resulted in a 55% increase in human sdLDL oxidation as compared to non-glucose-treated controls as measured by a marker of oxidation (malondialdehyde (MDA)). EPA inhibited this glucose-induced sdLDL oxidation in a dose-dependent fashion and, at the highest concentration tested (10.0 µM), EPA inhibited sdLDL oxidation by 94% compared to vehicle treated (ethanol) control.
Additional studies are needed to determine if the effects of EPA shown in this study would have clinically meaningful benefit in the human body.
This poster was presented by Dr. R. Preston Mason, PhD, of Brigham and Women's Hospital. Dr. Mason is also the President and Founder of Elucida Research.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. For more information about Amarin visit www.amarincorp.com.
This press release contains forward-looking statements, including statements about the potential efficacy, safety and therapeutic benefits of EPA, including statements about the potential clinical importance of the findings presented. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with in vitro research, research and development and clinical trials, including the risk that in vitro study results may not be predictive of future results or replicated in study in man and that studied parameters may not have clinically meaningful effect. A list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.Michael Farrell Investor Relations and Corporate Communications Amarin Corporation plc In U.S.: +1 (908) 719-1315Graham Morrell Trout Group In U.S.: +1 (646) 378-2954Lee Davies Makovsky In U.S.: +1 (212) 508-9651NEXT ARTICLE
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...